Cargando…
Current neoadjuvant treatment options for HER2-positive breast cancer
Approximately one quarter of patients with breast cancer demonstrate amplification of the human epidermal receptor type 2 (HER2) gene, the expression of which is associated with a relatively poor prognosis independent of other clinical and pathologic variables. Trastuzumab, a humanized recombinant m...
Autores principales: | Abdel-Razeq, Hikmat, Marei, Lina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156251/ https://www.ncbi.nlm.nih.gov/pubmed/21847344 http://dx.doi.org/10.2147/BTT.S22917 |
Ejemplares similares
-
Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression
por: Horani, Malek, et al.
Publicado: (2023) -
Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022) -
Surgical options for patients with early-stage breast cancer and pathogenic germline variants: an oncologist perspectives
por: Abdel-Razeq, Hikmat
Publicado: (2023) -
Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022) -
Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)